{"id":876287,"date":"2025-08-15T10:25:12","date_gmt":"2025-08-15T14:25:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/"},"modified":"2025-08-15T10:25:12","modified_gmt":"2025-08-15T14:25:12","slug":"altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/","title":{"rendered":"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Aug. 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in <b>Altimmune, Inc.<\/b> (&#8220;Altimmune&#8221; or the &#8220;Company&#8221;) (NASDAQ: ALT) of a class action securities lawsuit.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" title=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" alt=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>CLASS DEFINITION: <\/b>The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by <span>alleged<\/span> securities <span>fraud<\/span> between <span class=\"xn-chron\">August 10, 2023<\/span> and <span class=\"xn-chron\">June 25, 2025<\/span>. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p class=\"prntac\">\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4489079-4&amp;h=931139199&amp;u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Faltimmune-inc-lawsuit-submission-form-2%3Fprid%3D161443%26wire%3D4&amp;a=https%3A%2F%2Fzlk.com%2Fpslra-1%2Faltimmune-inc-lawsuit-submission-form-2%3Fprid%3D161443%26wire%3D4\" target=\"_blank\" rel=\"nofollow\">https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=161443&amp;wire=4<\/a>\u00a0<\/p>\n<p>\n        <b>ALT<\/b>\u00a0investors may also contact <span class=\"xn-person\">Joseph E. Levi, Esq.<\/span> via email <a href=\"mailto:at\u00a0jlevi@levikorsinsky.com\u00a0or\" rel=\"nofollow\">at\u00a0jlevi@levikorsinsky.com\u00a0or<\/a> by telephone at (212) 363-7500.<\/p>\n<p>\n        <b>CASE DETAILS: <\/b>According to the complaint, on <span class=\"xn-chron\">June 26, 2025<\/span>, Altimmune published a press release announcing topline results from the IMPACT Phase <span class=\"xn-money\">2b<\/span> MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase <span class=\"xn-money\">2b<\/span> MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial.\u00a0 Following this news, the price of Altimmune&#8217;s common stock declined dramatically. From a closing market price of <span class=\"xn-money\">$7.71<\/span> per share on <span class=\"xn-chron\">June 25, 2025<\/span>, Altimmune&#8217;s stock price fell to <span class=\"xn-money\">$3.61<\/span> per share on <span class=\"xn-chron\">June 26, 2025<\/span>, a decline of 53.2% in the span of just a single day.<\/p>\n<p>\n        <b>WHAT&#8217;S NEXT? <\/b>If you suffered a loss in Altimmune during the relevant time frame, you have until <b><span class=\"xn-chron\">October 6, 2025<\/span><\/b>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <b>NO COST TO YOU: <\/b>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <b>There is no cost or obligation to participate.<\/b><\/p>\n<p>\n        <b>WHY LEVI &amp; KORSINSKY: <\/b>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services&#8217; Top 50 Report as one of the top securities litigation firms in <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/><span class=\"xn-person\">Joseph E. Levi, Esq.<\/span><br \/><span class=\"xn-person\">Ed Korsinsky, Esq.<\/span><br \/>33 Whitehall Street, 17th Floor<br \/><span class=\"xn-location\">New York, NY<\/span> 10004<br \/><a href=\"mailto:jlevi@levikorsinsky.com\" target=\"_blank\" rel=\"nofollow\">jlevi@levikorsinsky.com<\/a>\u00a0<br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4489079-4&amp;h=3683372104&amp;u=https%3A%2F%2Fwww.zlk.com%2F&amp;a=www.zlk.com\" target=\"_blank\" rel=\"nofollow\">www.zlk.com<\/a>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY52133&amp;sd=2025-08-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi--korsinsky-before-october-6-2025-to-discuss-your-rights--alt-302530609.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi&#8211;korsinsky-before-october-6-2025-to-discuss-your-rights&#8211;alt-302530609.html<\/a><\/p>\n<p>SOURCE  Levi &amp; Korsinsky, LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY52133&amp;Transmission_Id=202508150915PR_NEWS_USPR_____NY52133&amp;DateId=20250815\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Altimmune, Inc. (&#8220;Altimmune&#8221; or the &#8220;Company&#8221;) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=161443&amp;wire=4\u00a0 ALT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876287","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Altimmune, Inc. (&#8220;Altimmune&#8221; or the &#8220;Company&#8221;) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=161443&amp;wire=4\u00a0 ALT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide &hellip; Continue reading &quot;Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T14:25:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT\",\"datePublished\":\"2025-08-15T14:25:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/\",\"name\":\"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2025-08-15T14:25:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Market Newsdesk","og_description":"PR Newswire NEW YORK , Aug. 15, 2025 \/PRNewswire\/ &#8212; Levi &amp;\u00a0Korsinsky, LLP notifies investors in Altimmune, Inc. (&#8220;Altimmune&#8221; or the &#8220;Company&#8221;) (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/altimmune-inc-lawsuit-submission-form-2?prid=161443&amp;wire=4\u00a0 ALT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide &hellip; Continue reading \"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-15T14:25:12+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT","datePublished":"2025-08-15T14:25:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/"},"wordCount":493,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/","name":"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2025-08-15T14:25:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-inc-securities-fraud-class-action-lawsuit-pending-contact-levi-korsinsky-before-october-6-2025-to-discuss-your-rights-alt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 6, 2025 to Discuss Your Rights &#8211; ALT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876287"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876287\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}